Mesalazine
When ATH:
A07EC02
Pharmacological action.
Anti-inflammatory.
Application.
Inflammatory bowel disease (nespetsificheskiy yazvennыy colitis, Crohn's disease), in the acute phase and prevention their recurrence.
Contraindications.
Hypersensitivity (incl. other derivatives of salicylic acid), expressed human liver and kidneys, blood disease, gyemorragichyeskii diatyez, gastric ulcer and duodenal ulcer, pregnancy, lactation, infancy (to 2 years).
Side effects.
Discomfort, abdominal pains, nausea, flatulence, frequent urge to defecate, aggravation of hemorrhoids, hyperthermia, flu-like syndrome and acute intolerance (gripes, bloody flux, fever, headache, rash), asthenia, drug lupus syndrome, artralgii, alopecia, metgemoglobinemiâ, transaminase elevation, alkaline phosphatase, creatinine, BUN, allergic skin rashes.
Cooperation.
Enhances ulzerogennosti glucocorticoids, the toxicity of methotrexate, hypoglycemic effect of sulfonylureas, hypoprotrombinemic - anticoagulants. It slows down the absorption of cyanocobalamin. It weakens the activity of furosemide, spironolactone, rifampicin.
Dosing and Administration.
Inside, without chewing, drinking plenty of water: adults with exacerbation - by 1 g 4 once a day, Supporting doses - 500 mg 3 once a day with non -specific ulcerative colitis and 1 g 4 twice daily for Crohn's disease; Children over 2 years old-20-30 mg/kg/day in several receptions. In severe disease, the daily dose can be increased to 3-4 g, but no more than 8-12 weeks. Rectal (After emptying the rectum): if proctitis, proctosigmoiditis and left-sided ulcerative colitis for adults 1 supp. 1-2 Times a day. In the form of medicinal microclisms - 60 Mr. Suspensions 1 once a day, before bedtime.
Precautions.
Before, during (1-2 Times per month), and after treatment (every 3 Months) should control the peripheral blood, the level of urea, creatinine, general urine analysis. If you suspect an acute intolerance syndrome development mesalazine should be abolished. However, it should be taken into account, acute intolerance syndrome that in some cases it can be difficult to differentiate from a severe exacerbation of inflammatory bowel disease.
Cooperation
Active substance | Description of interaction |
Methotrexate | FMR. Against the background of mesalazine enhanced probability of kidney damage. |
Rifampicin | FMR: antagonizm. Against the background of the effect of mesalazine decreases. |
Spironolactone | FMR: antagonizm. Against the background of the effect of mesalazine decreases. |
Furosemid | FMR: antagonizm. Against the background of the effect of mesalazine decreases. |
Цianokoʙalamin | FKV. Against the backdrop of slowing down the absorption of mesalazine. |